Shares of Regenxbio Inc. (RGNX) gained 5% on Wednesday morning after the company reported positive biomarker data from Affinity Duchenne trial of RGX-202 gene therapy.
RGNX is currently trading at $8.21, up $0.41 or 5.26%, on the Nasdaq. The stock opened its trading at $7.90 after closing Tuesday at $7.80. The stock has traded between $5.62 and $23.14 in the past 52-week period.
Regenxbio reported new, positive interim data from two additional patients in the Phase I/II portion of the Affinity Duchenne trial of RGX-202, a differentiated investigational gene therapy for Duchenne muscular dystrophy (Duchenne).
"RGX-202 is the only next generation gene therapy for Duchenne in a pivotal phase trial. The new data from the age 1-3 cohort builds on the favorable safety and efficacy profile seen in ages 4 and older and reinforces the potential of RGX-202 to serve a wide age range of patients," said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO.
"The consistent, robust microdystrophin levels seen across the age range as well as the functional improvements previously reported support RGX-202's potential to alter the course of this devastating disease. We look forward to sharing additional Phase I/II functional data in the first half of 2025. We also continue to rapidly advance the pivotal trial towards completing enrollment this year and BLA submission mid-2026."
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.